Patents by Inventor Clinton A. Brooks

Clinton A. Brooks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240043428
    Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
    Type: Application
    Filed: December 21, 2022
    Publication date: February 8, 2024
    Inventors: Gilbert BESONG, Christopher Thomas BRAIN, Clinton A. BROOKS, Miles Stuart CONGREVE, Claudio DAGOSTIN, Guo HE, Ying HOU, Steven HOWARD, Yue LI, Yipin LU, Paul MORTENSON, Troy SMITH, Moo Je SUNG, Steven WOODHEAD, Wojciech WRONA, Bharat LAGU
  • Publication number: 20210253578
    Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
    Type: Application
    Filed: September 16, 2020
    Publication date: August 19, 2021
    Inventors: Gilbert BESONG, Christopher Thomas BRAIN, Clinton A. BROOKS, Miles Stuart CONGREVE, Claudio DAGOSTIN, Guo HE, Ying HOU, Steven HOWARD, Yue LI, Yipin LU, Paul MORTENSON, Troy SMITH, Moo Je SUNG, Steven WOODHEAD, Wojciech WRONA, Bharat LAGU
  • Publication number: 20180155351
    Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
    Type: Application
    Filed: February 1, 2018
    Publication date: June 7, 2018
    Inventors: Gilbert Besong, Christopher Thomas Brain, Clinton A. Brooks, Miles Stuart Congreve, Claudio Dagostin, Guo He, Ying Hou, Steven Howard, Yue Li, Yipin Lu, Paul Mortenson, Troy Smith, Moo Je Sung, Steven Woodhead, Wojciech Wrona, Bharat Lagu
  • Publication number: 20170183352
    Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
    Type: Application
    Filed: August 8, 2016
    Publication date: June 29, 2017
    Applicants: Novartis AG, Astex Therapeutics Ltd.
    Inventors: Gilbert BESONG, Christopher Thomas BRAIN, Clinton A. BROOKS, Miles Stuart CONGREVE, Claudio DAGOSTIN, Guo HE, Ying HOU, Steven HOWARD, Yue LI, Yipin LU, Paul MORTENSON, Troy SMITH, Moo Je SUNG, Steven WOODHEAD, Wojciech WRONA, Bharat LAGU
  • Patent number: 9416136
    Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: August 16, 2016
    Assignees: Novartis AG, Astex Therapeutics, Ltd.
    Inventors: Gilbert Besong, Christopher Thomas Brain, Clinton A Brooks, Miles Stuart Congreve, Claudio Dagostin, Guo He, Ying Hou, Steven Howard, Yue Li, Yipin Lu, Paul Mortenson, Troy Smith, Moo Je Sung, Steven Woodhead, Wojciech Wrona, Bharat Lagu
  • Publication number: 20140135312
    Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
    Type: Application
    Filed: January 17, 2014
    Publication date: May 15, 2014
    Applicants: Astex Therapeutics Ltd., Novartis AG
    Inventors: Gilbert BESONG, Christopher Thomas Brain, Clinton A. Brooks, Miles Stuart Congreve, Claudio Dagostin, Guo He, Ying Huo, Steven Howard, Yue Ll, Yipin Lu, Paul Mortenston, Troy Smith, Moo Je Sung, Steven Woodhead, Wojciech Wrona, Bharat Lagu
  • Publication number: 20110152244
    Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
    Type: Application
    Filed: August 20, 2009
    Publication date: June 23, 2011
    Applicants: NOVARTIS AG, ASTEX THERAPEUTICS LTD.
    Inventors: Gilbert Besong, Christopher Thomas Brain, Clinton A. Brooks, Miles Stuart Congreve, Claudio Dagostin, Guo He, Ying Huo, Steven Howard, Yue Li, Yipin Lu, Paul Morteson, Troy Smith, Moo Sung, Steven Woodhead, Wojciech Wrona
  • Publication number: 20110060009
    Abstract: The present teachings relate to compounds of Formula I: and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R1, R2, R3, R4, R5, ring A, and Z are as defined herein. The present teachings also provide methods of preparing compounds of Formula I and methods of use compounds of Formula I in treating pathologic conditions or disorders mediated wholly or in part by deacetylases.
    Type: Application
    Filed: August 27, 2010
    Publication date: March 10, 2011
    Inventors: Clinton A. BROOKS, Christine Hiu-Tung CHEN, Young Shin CHO, Lei JIANG, Gang LIU, Michael SHULTZ
  • Publication number: 20100105653
    Abstract: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
    Type: Application
    Filed: August 21, 2009
    Publication date: April 29, 2010
    Inventors: Gilbert Besong, Christopher Thomas Brain, Clinton A. Brooks, Miles Stuart Congreve, Claudio Dagostin, Guo He, Ying Huo, Steven Howard, Yue Li, Yipin Lu, Paul Mortenson, Troy Smith, Moo Je Sung, Steven Woodhead, Wojciech Wrona
  • Publication number: 20100048539
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to beat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFR? and PDGFR? kinases. Formula (I).
    Type: Application
    Filed: November 2, 2007
    Publication date: February 25, 2010
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Donatella Chianelli, Xiaolin Li, Xiaodong Liu, Jon Loren, Valentina Molteni, Juliet Nabakka, Laszlo Revesz, Lawrence B. Perez, Clinton Brooks, Wojciech Wrona, Paul William Manley, Werner Breitenstein